Genmab A/S (GMAB)

Genmab A/S (Healthcare) holds an AlphaScore of 64/100 as of 2026-10-11, earning a grade of B and a Watch signal. The record indicates a high gross margin of 93.6% and a net margin of 25.89%. A primary strength is the robust revenue growth of 19.19%. A notable risk is the elevated debt-to-equity ratio of 0.89. Evidence is limited strictly to the provided dataset.

Written 11/10/2026, 00:32:17 UTC · Snapshot 11/10/2026